CL2021003222A1 - (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. - Google Patents

(divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Info

Publication number
CL2021003222A1
CL2021003222A1 CL2021003222A CL2021003222A CL2021003222A1 CL 2021003222 A1 CL2021003222 A1 CL 2021003222A1 CL 2021003222 A CL2021003222 A CL 2021003222A CL 2021003222 A CL2021003222 A CL 2021003222A CL 2021003222 A1 CL2021003222 A1 CL 2021003222A1
Authority
CL
Chile
Prior art keywords
peripheral arterial
statins
reducing
methods
need
Prior art date
Application number
CL2021003222A
Other languages
English (en)
Inventor
Craig Granowitz
Sephy Philip
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of CL2021003222A1 publication Critical patent/CL2021003222A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Uso de una composición farmacéutica que comprende aproximadamente 1 g a aproximadamente 4 g de éster etílico del ácido eicosapentaenoico en un sujeto con un nivel inicial de triglicéridos en ayunas de al menos aproximadamente 150 mg/dl, que sirve para preparar un medicamento útil en el tratamiento de riesgo de revascularización arterial periférica.
CL2021003222A 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas. CL2021003222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
CL2021003222A1 true CL2021003222A1 (es) 2022-07-22

Family

ID=69524891

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2021000400A CL2021000400A1 (es) 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2021003222A CL2021003222A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2021003221A CL2021003221A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2021000400A CL2021000400A1 (es) 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021003221A CL2021003221A1 (es) 2018-08-17 2021-12-03 (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.

Country Status (18)

Country Link
US (1) US20220362200A1 (es)
EP (1) EP3836914A4 (es)
JP (1) JP2021534185A (es)
KR (1) KR20210047312A (es)
CN (1) CN112912071A (es)
AU (1) AU2019321568A1 (es)
BR (1) BR112021002884A2 (es)
CA (1) CA3109774A1 (es)
CL (3) CL2021000400A1 (es)
EA (1) EA202190547A1 (es)
IL (1) IL280643A (es)
MA (1) MA52680A1 (es)
MX (1) MX2021001906A (es)
NI (1) NI202100009A (es)
PH (1) PH12021550328A1 (es)
SG (1) SG11202101562UA (es)
TN (1) TN2021000028A1 (es)
WO (1) WO2020037153A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2538691C2 (ru) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Стабильные фармацевтические композиции и способы их применения
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
LT3318255T (lt) 2009-06-15 2021-05-25 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP4342546A3 (en) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US11645899B2 (en) 2018-09-14 2023-05-09 Avive Solutions, Inc. Responder network
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
CA3154933A1 (en) * 2019-11-21 2021-05-27 Micah R. Bongberg Device based responder network activation and virtual assistant integration
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
AU2022264041A1 (en) * 2021-04-29 2023-11-16 Amarin Pharmaceuticals Ireland Limited Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
JP2009544701A (ja) * 2006-07-21 2009-12-17 リライアント・ファーマシューティカルズ・インコーポレイテッド オメガ３脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用
EP4342546A3 (en) * 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014179325A1 (en) * 2013-04-29 2014-11-06 Matinas Biopharma, Inc. Omega-3 fatty acid formulations for use as pharmaceutical treatment
CN114642661A (zh) * 2014-03-17 2022-06-21 赛诺菲生物技术公司 用于降低心血管风险的方法
US10406130B2 (en) * 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
ES2847168T5 (es) * 2016-07-29 2024-02-20 Kowa Co Métodos para prevenir acontecimientos cardiovasculares en poblaciones dislipidémicas de riesgo residual

Also Published As

Publication number Publication date
CN112912071A (zh) 2021-06-04
NI202100009A (es) 2021-06-22
WO2020037153A1 (en) 2020-02-20
MX2021001906A (es) 2021-04-28
JP2021534185A (ja) 2021-12-09
TN2021000028A1 (en) 2022-10-03
IL280643A (en) 2021-03-25
AU2019321568A1 (en) 2021-03-11
CA3109774A1 (en) 2020-02-20
EP3836914A4 (en) 2022-05-18
PH12021550328A1 (en) 2021-10-04
EP3836914A1 (en) 2021-06-23
MA52680A1 (fr) 2021-11-30
KR20210047312A (ko) 2021-04-29
US20220362200A1 (en) 2022-11-17
SG11202101562UA (en) 2021-03-30
CL2021003221A1 (es) 2022-07-22
BR112021002884A2 (pt) 2021-05-11
CL2021000400A1 (es) 2021-07-02
EA202190547A1 (ru) 2021-04-27

Similar Documents

Publication Publication Date Title
CL2021003222A1 (es) (divisional de solicitud 400-2021) métodos para reducir la necesidad de revascularización arterial periférica en un sujeto tratado con estatinas.
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
NI201400155A (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
MX2022005467A (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto con fibrilación auricular y/o aleteo auricular.
RU2013121788A (ru) Ингибиторы репликации вич
RU2017112149A (ru) Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени
BR112017010689A2 (pt) ?composição, processo cosmético e uso cosmético da composição e de éster de ácido?
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112017027909A2 (pt) composição, e, uso de uma composição
CO6531499A2 (es) Uso de ranolazina para el tratameinto de enfermedades cardiovasculares
CO6400019A1 (es) Composicion farmaceutica que comprende racetam y carnitina y proceso para su preparacion
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
CO2023007955A2 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina fosfolipasa d
PH12021500016A1 (en) Methods of reducing the risk of cardiovascular events in a subject
CO2023007903A2 (es) Ésteres de ácido dicarboxílico para inducir un efecto analgésico
AR111816A1 (es) Composiciones y métodos para reducir los triglicéridos en un sujeto que tiene función renal reducida
EA202190269A1 (ru) Фармацевтическая композиция в виде жевательной таблетки диосмина или флавоноидной фракции